Despite improvement in pathologic complete response with preoperative chemoradiation, the benefit did not extend to overall ...

2024年9月13日-17日，欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那召开，作为肿瘤内科最高规模的国际盛会，涉及肺癌、乳腺癌、消化道肿瘤、泌尿生殖系统肿瘤等领域的多项研究届时皆将披露最新进展。

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

阿斯利康中国副总裁、肿瘤业务肺癌事业部负责人张凌燕表示：“很激动看到ADRIATIC研究再获殊荣，阿斯利康非常荣幸能够通过这些科学研究助力更多中国肺癌专家在国际舞台发挥越来越重要的影响力。作为一家以科学为本的全球领先制药企业，我们在中国肺癌领域深耕的 ...

The following is a summary of “Dose-response relationships between radiation exposure, bone marrow function as measured by ...

Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial ...

Locally advanced cervical cancer accounts for around 40% of all cervical cancers.1 Cisplatin-based chemoradiotherapy followed ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...